PDE4 inhibitors are associated with anti-inflammatory and antifibrotic effects, and have the potential to reduce inflammation and fibrotic remodelling in lung diseases, as described above (“Pre-clinical evidence for targeting PDE4 in lung fibrosis”). Here, PDE4A is linked to pulmonary fibrosis.